image

Key updates

What's new on Wikilite
Section Contents
  • What's new on Wikilite
    • Key updates


Date Publication Update
29/03/2017
IMW 2017 abstracts Section 8.2. Overview of commercial FLC assays
Section 12.4. Improving our understanding of disease pathogenesis and response to therapy
Section 18.3.5. Monitoring patients treated with monoclonal antibody-based therapies
Section 18.4.1. HLC assays are quantitative and non-subjective
Section 20.2. sFLCs at diagnosis
Section 20.5. HLC analysis during response assessment
24/02/2017
Murata 2016 [937]Section 18.3.5. Monitoring patients treated with monoclonal antibody-based therapies
24/02/2017
Tacchetti 2016 [938]Section 20.3.3. Prognostic implications of relapse with FLCs
24/02/2017
Sarto 2016 [936]Section 11.5.1. Comparison of Hevylite and total immunoglobulin measurements
Section 11.5.2. Comparison of Hevylite and immmunoglobulin measurements by SPE
24/02/2017
Murata 2016 [937]Section 18.3.5. Monitoring patients treated with monoclonal antibody-based therapies
21/12/2016
Voortman 2016 [934]Section 36.2. CSF FLCs as a marker of intrathecal immunoglobulin synthesis
Section 36.3. Prognostic significance of CSF FLCs
21/12/2016
Zeman 2016 [933]Section 36.2. CSF FLCs as a marker of intrathecal immunoglobulin synthesis
21/12/2016
Dobson 2013 [935]Section 36.3. Prognostic significance of CSF FLCs
16/10/2016
Dejoie 2016 [914]Section 15.1. Diagnosis of Light chain multiple myeloma
*NEW* Figure 15.4. Sensitivity of serum and urine FLC measurements.
Section 15.2. Monitoring light chain multiple myeloma
Section 20.3.1. Normalisation of the sFLC ratio and importance of a sCR
Section 20.3.2. Early sFLC response predicts outcome
Section 24.8. Comparison of sFLCs and urinalysis for monitoring patients
*NEW* Figure 24.7. Survival outcomes according to serum and urine FLC characteristics at end of induction therapy.
*NEW* Figure 24.8. Abnormal sFLC measurements stratify patients with normal urine results after induction.

Figures